These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2432676)

  • 21. Clearance of thrombin from circulation in rabbits by high-affinity binding sites on endothelium. Possible role in the inactivation of thrombin by antithrombin III.
    Lollar P; Owen WG
    J Clin Invest; 1980 Dec; 66(6):1222-30. PubMed ID: 6255009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of thrombin and endotoxin on the in vivo metabolism of antithrombin III (AT III) in dogs.
    Tanaka H; Kobayashi N; Maekawa T
    Thromb Res; 1985 Nov; 40(3):291-306. PubMed ID: 4082111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of heparin, hirudin, and a synthetic thrombin inhibitor on antithrombin III in thrombin-induced disseminated intravascular coagulation in rats.
    Hauptmann J; Brüggener E; Markwardt F
    Haemostasis; 1987; 17(6):321-8. PubMed ID: 3428717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction of human alpha-thrombin and gamma-thrombin with antithrombin III, protein C and thrombomodulin.
    Bezeaud A; Denninger MH; Guillin MC
    Eur J Biochem; 1985 Dec; 153(3):491-6. PubMed ID: 3000780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasmin inhibitors in different fibrinolytic treatment patterns.
    Lasierra J; Diez M; Perera C; Viladés E
    Haemostasis; 1981; 10(1):51-62. PubMed ID: 6162721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperproduction of fibrin and inefficacy of antithrombin III and alpha2 macroglobulin in the presence of bacterial porins.
    Di Micco B; Di Micco P; Lepretti M; Stiuso P; Donnarumma G; Iovene MR; Capasso R; Tufano MA
    Int J Exp Pathol; 2005 Aug; 86(4):241-5. PubMed ID: 16045546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemostatic balance during the acute inflammatory reaction; with special reference to antithrombin III.
    Pleşca LA; Bodizs G; Cucuianu M; Colhon D
    Rom J Physiol; 1995; 32(1-4):71-6. PubMed ID: 8896078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antithrombin activity of a fucan sulfate from the brown seaweed Ecklonia kurome.
    Nishino T; Aizu Y; Nagumo T
    Thromb Res; 1991 Jun; 62(6):765-73. PubMed ID: 1926066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Course and resolution of the coagulopathy in nephrotic children.
    Alkjaersig N; Fletcher AP; Narayanan M; Robson AM
    Kidney Int; 1987 Mar; 31(3):772-80. PubMed ID: 2437352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Proteinase inhibitors and fibrinogen split products in patients with malignant diseases (author's transl)].
    Schwarz HP; Aiginger P; Kuzmits R
    Acta Med Austriaca; 1981; 8(1):22-5. PubMed ID: 6165218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A kinetic study on the effects of anticoagulants on the interaction of fibrinogen and thrombin.
    Nakanishi E; Sato H; Nakajima A
    J Biomed Mater Res; 1987 Feb; 21(2):187-200. PubMed ID: 2434508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is the imbalance between thrombin and plasmin activity in diabetes related to the behaviour of antiplasmin activity?
    Marongiu F; Conti M; Mameli G; Sorano GG; Cossu E; Cirillo R; Balestrieri A
    Thromb Res; 1990 Apr; 58(2):91-9. PubMed ID: 1693451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibrinogen, D-dimer and thrombin-antithrombin complexes in a random population sample: relationships with other cardiovascular risk factors.
    Giansante C; Fiotti N; Cattin L; Da Col PG; Calabrese S
    Thromb Haemost; 1994 May; 71(5):581-6. PubMed ID: 8091384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Haemostatic changes related to extracorporeal circulation (ECC) (author's transl)].
    Witzke G; Elert O
    Anaesthesist; 1981 Feb; 30(2):64-70. PubMed ID: 6164310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Substitution of antithrombin III by synthetic thrombin inhibitors].
    Hauptmann J; Brüggener E; Müller H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(4):550-5. PubMed ID: 6083925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new assay for the measurement of total progressive antithrombin.
    Lane JL; Bird P; Rizza CR
    Br J Haematol; 1975 May; 30(1):103-15. PubMed ID: 53064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the inhibition of thrombin by three plasma protease inhibitors.
    Downing MR; Bloom JW; Mann KG
    Biochemistry; 1978 Jun; 17(13):2649-53. PubMed ID: 79421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interaction of antithrombin III and thrombin-antithrombin III complex with cultured aortic endothelial cells.
    Bartha K; Kovács T; Léránt I; Papp B; Csonka E; Kolev K; Machovich R
    Thromb Res; 1987 Sep; 47(5):541-52. PubMed ID: 3672436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interactions of human mast cell tryptase with biological protease inhibitors.
    Alter SC; Kramps JA; Janoff A; Schwartz LB
    Arch Biochem Biophys; 1990 Jan; 276(1):26-31. PubMed ID: 1688695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The transient increase of plasma thrombin-antithrombin III (TAT) complex levels in patients with congenital antithrombin III deficiency during antithrombin III administration is due to extraction of thrombin from fibrin.
    Kario K; Matsuo T; Kabayashi H; Matsuo M; Yamamoto K
    Thromb Res; 1991 Aug; 63(4):469-72. PubMed ID: 1755000
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.